ANGLE Plc - UK-based liquid biopsy company - Parsortix system was successfully used to harvest cancer cells from the blood of patients with brain metastasis.
Brain metastasis is the most common type of brain tumor, accounting for more than 88% of cases.
Chief Executive Andrew Newland says: "This is important new work by the world-leading Hamburg-Eppendorf cancer centre. Wikman and her team have demonstrated the utility of the Parsortix system in isolating CTCs from cancer brain metastases and demonstrated superior CTC positivity rates than those seen in studies using other enrichment technologies. Cancer brain metastases cannot be accessed for tissue biopsy without highly invasive procedures and a liquid biopsy alternative would be of great benefit to patients to monitor and optimise treatment."
Current stock price: 123.00 pence
Year-to-date change: up sharply from 47.75p
By Aidan Lane; newsroom@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Angle (AGL)